GlassScriptPhysician profile
Daniel Eugene Bruckner
NPI 1134432446
$22,566.38
in general payments reported to CMS, 2019-2025
32 companies · $1,926 in 2025
The $1,926 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $628 · 2021: $15K · 2022: $387 · 2023: $2,487 · 2024: $2,093 · 2025: $1,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,755 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,755.23 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofire Diagnostics, LLC | $14,719.18 | 2019-2021 | |
| Biomerieux INC | $1,944.27 | 2021-2025 | Biofire Spotfire Respiratory/Sore Throat (R/St) Panel |
| Supernus Pharmaceuticals, INC. | $900.94 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $546.16 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $482.04 | 2019-2025 | Gardasil 9, Enflonsia, M-M-R II |
| Regeneron Healthcare Solutions, INC. | $434.91 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $411.34 | 2020-2025 | Penmenvy, Bexsero, Pediarix |
| Tris Pharma INC | $336.39 | 2019-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Kaleo, INC. | $316.43 | 2020-2024 | Auvi-Q |
| Sanofi Pasteur INC. | $283.57 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $260.46 | 2024-2025 | |
| Novo Nordisk INC | $249.91 | 2024-2025 | Wegovy, Saxenda |
| Pfizer INC. | $215.54 | 2019-2025 | |
| Kls-Martin L.P. | $180.13 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $178.97 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $176.66 | 2025 | Neffy |
| Cranial Technologies, INC | $167.57 | 2019-2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $164.24 | 2025 | Jornay Pm |
| Verrica Pharmaceuticals INC. | $148.80 | 2024-2025 | Ycanth |
| Abbott Laboratories | $69.20 | 2023-2025 | Id Now Instrument |
| Seqirus USA INC | $68.58 | 2023-2025 | Flucelvax Quadrivalent, Fluad, Flucelvax |
| Vertical Pharmaceuticals, LLC | $45.83 | 2019-2025 | Relexxii |
| Alk-Abello, INC | $45.61 | 2025 | Neffy |
| Noven Therapeutics, LLC | $45.03 | 2025 | Xelstrym |
| Harmony Biosciences LLC | $31.47 | 2024 | |
| Neos Therapeutics, LP | $29.90 | 2025 | Cotempla Xr-Odt |
| Ultragenyx Pharmaceutical INC. | $23.66 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $21.03 | 2024 | Flumist Quadrivalent |
| Lnhc, INC | $19.88 | 2025 | Zelsuvmi |
| Genentech USA, INC. | $19.09 | 2019 | |
| Cognoa, INC. | $15.32 | 2022 | |
| Adlon Therapeutics L.P. | $14.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bruckner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.